Manufacturing generic drugs is an important part of the global health system because it offers low-cost alternatives to Brand Name Medicines. Once the patent for a Brand Name Drug has expired, companies can begin producing a Generic version of that Drug for sale in the same market.
Generic Products have all of the same ingredients, dosage forms, Strengths, Route of Administration and Intended Use as the brand named Original Product. Because they have the same clinical effect as the Original Product, generic drugs also reduce the cost of providing healthcare to consumers.
The approval and Manufacturing of Generic Drugs are monitored by Regulatory Bodies including but not limited to: the USA FDA; the European Medicines Agency (EMA) the Central Drugs Standard Control Organization of India (CDSCO) and others. These Regulatory Bodies confirm that Generic Drugs being manufactured and sold are safe, effective and of good quality.
Manufacturing Generic Drugs provides pharmaceutical companies with a lot of opportunities; however, it can also pose many regulatory, technical and commercial challenges.
Because the original manufacturers have done all of the expensive clinical and research studies, a generic manufacturer does not have to do this for its generic products. However, they do have to show that their generic will perform in the same way as the original manufacturer.
The regulatory path used for generic drugs tremendously decreases the development cost and allows the generic drug to be made available sooner after the expiration of the patent on the original drug.
Further, many of the fastest-growing markets are found in the developing countries of Asia, Africa and Latin America, which is directly related to the increasing availability of affordable and accessible healthcare and the anticipated population growth of these regions.
Some common compliance issues that manufacturers face include:
Some examples of these drugs are:
There can be disruptions in supply chains from:
These barriers place additional time delays on generic drugs entering the market and create substantial legal hurdles for manufacturers.
To ensure that all reference drugs are of equal value there has to be;
1. Bioequivalence with their respective reference drugs.
2. Consistent methodological practices in all processes used to manufacture generic drugs.
3. High standards of product quality.
4. Accurate documentation.
5. Strong quality management system.
Regulatory agencies frequently perform inspections of facilities for compliance to these criteria with a focus on data integrity, process validation and acceptable documentation practices. Companies that have a strong compliance program generally will have the best opportunity for success in the global market.
1. Growth of complex generics.
2. Increased levels of automation in the manufacturing process.
3. Implementation of digital quality management systems.
4. Expansion of the biosimilars market.
5. Improved regulatory collaboration among countries.
The increasing number of these trends are expected to improve efficiency while providing for continued high quality.
Global pharmaceutical generating manufacturing is an important part of the pharmaceutical industry. Generics enable many millions of people around the world to access healthcare by providing lower-cost alternatives to branded products.
The generic drug industry presents pharmaceutical companies with great opportunity; however, it also creates challenges like competition, compliance with regulation and having to meet complicated manufacturing rules.
Pharmaceutical companies that focus on manufacturing of high-quality generics efficiently and comply with regulatory requirements will continue to have best position in the competitive generics market. Generics will continue to play a crucial role in helping to improve access to healthcare globally due to continuing demand for low-cost medications.
The approval and Manufacturing of Generic Drugs are monitored by Regulatory Bodies including but not limited to: the USA FDA; the European Medicines Agency (EMA) the Central Drugs Standard Control Organization of India (CDSCO) and others. These Regulatory Bodies confirm that Generic Drugs being manufactured and sold are safe, effective and of good quality.
Manufacturing Generic Drugs provides pharmaceutical companies with a lot of opportunities; however, it can also pose many regulatory, technical and commercial challenges.
Understanding Generic Drugs
The definition of a "generic drug" is one that is chemically identical to an approved brand-name prescription. These are regulated as bioequivalent meaning they have the same amount of active ingredient delivered into a patient's blood stream over the same period of time as an FDA approved "originator" or brand name prescription.Because the original manufacturers have done all of the expensive clinical and research studies, a generic manufacturer does not have to do this for its generic products. However, they do have to show that their generic will perform in the same way as the original manufacturer.
The regulatory path used for generic drugs tremendously decreases the development cost and allows the generic drug to be made available sooner after the expiration of the patent on the original drug.
The Growing Importance of Generic Drugs
Generic drugs play an ever-increasing role (over 80 percent) in all medications used worldwide and have grown due in part to:- The expiration of patents on numerous blockbuster medications
- Healthcare costs increasing yet still needing affordable medicine
- Government policies to help promote affordable medicines
- Increased demand from developing nations
Opportunities in Generic Drug Manufacturing
At present, the opportunities available to pharmaceutical companies in the field of generic drug manufacturing are numerous and varied.1. Expanding Global Market
The most significant opportunity for generic drug manufacturers is that there is an ever-growing global demand for low-cost medicines. As a result, the number of countries that have implemented government initiatives encouraging the use of generics to lower healthcare costs is also increasing, resulting in the creation of a very large and stable global market for generics.Further, many of the fastest-growing markets are found in the developing countries of Asia, Africa and Latin America, which is directly related to the increasing availability of affordable and accessible healthcare and the anticipated population growth of these regions.
2. Lower Development Costs
Developing a new innovative compound can take an estimated 10 to 20 years and an investment of over $1 billion. Conversely, the development of a generic product typically incurs a much lower cost due mainly to the following three reasons:- Clinical trials typically are minimal,
- Safety and efficacy data already exist and
- Development cycles are faster.
3. Rapid Regulatory Processes
Generic medications in the U.S. are governed by the U.S. FDA's ANDA to approve drugs for sale. The ANDA application permits a manufacturer to show that a drug is bioequivalent to another drug without going through extensive clinical trials, thus speeding up its entry into the market.4. Loss of Patent Protections
Every year many patented medications reach the end of their patent protection. When this occurs, it is referred to as "the patent cliff." A generic drug manufacturer can introduce a product when a related brand-name medication loses its patent protection. Therefore, the generic manufacturer has a chance to gain market share as early as possible.5. Support and Policy Support for Generics
Many nations/ governments have programs to support their citizens with accessing medical treatment via generic medications as a way to reduce overall healthcare costs. Governments are working to create a favorable environment for generic medicines in the following ways:- Mandatory generic substitution by the pharmacists
- Public sector purchasing programs
- Setting maximum prices for drugs
Challenges to the Manufacturing of Generic Drugs
There are many obstacles associated with the manufacture of a generic drug and even though they provide benefits, some of these obstacles also create hardships.1. Large Amount of Competition
It is because of the vast number of companies producing the same generic drug that there is so much competition in the industry. Each month that more companies start producing a generic drug, the following happens:- The selling price of the generic drug drops
- Each company’s profit margin drops
- Each company’s share of the market shrinks
2. Regulatory Compliance
In addition to competing on cost, the generic manufacturers also must adhere to many regulatory requirements and logistics. For example, the manufacturers must comply with Good Manufacturing Practices (GMP) and be inspected by regulatory agencies such as the European Medicines Agency (EMA) and the Central Drugs Standard Control Organisation (CDSCO).Some common compliance issues that manufacturers face include:
- Data integrity issues
- Documentation issues
- Process Variability
- Quality System weaknesses
3. Complex Manufacturing Processes
The formulation of some drugs can be very challenging to manufacture. This is mostly the result of a complicated formulation with a specialized delivery system.Some examples of these drugs are:
- Controlled-release tablets
- Sterile injectable products
- Inhalation drugs
- Biologicals
4. Supply Chain Challenges
Pharmaceutical supply chains involve complex and geographical issues. Generic drug manufacturers must ensure an unobstructed source of raw materials and active Pharmaceutical Ingredients (APIs).There can be disruptions in supply chains from:
- Geopolitical issues
- Regulatory restrictions
- Transportation delays
- Quality problems at suppliers for raw materials
5. Intellectual Property Barriers
Many times once the patent has expired for a prescription drug, the branded drug company can submit additional legal claims to maintain monopoly. For example, they can submit a second patent or extend the monopoly based on exclusivity claims.These barriers place additional time delays on generic drugs entering the market and create substantial legal hurdles for manufacturers.
Quality and Compliance in Generic Manufacturing
The importance of quality and compliance cannot be overstated in generic drug production. Quality must be maintained at the same level as with a brand, despite the lower costs associated with generics. Generics must meet the same regulatory requirements that are associated with branded products.To ensure that all reference drugs are of equal value there has to be;
1. Bioequivalence with their respective reference drugs.
2. Consistent methodological practices in all processes used to manufacture generic drugs.
3. High standards of product quality.
4. Accurate documentation.
5. Strong quality management system.
Regulatory agencies frequently perform inspections of facilities for compliance to these criteria with a focus on data integrity, process validation and acceptable documentation practices. Companies that have a strong compliance program generally will have the best opportunity for success in the global market.
The Future of Generic Drug Manufacturing
As the generic pharmaceutical industry evolves due to changes in technology and regulatory requirements, the following trends are expected to continue:1. Growth of complex generics.
2. Increased levels of automation in the manufacturing process.
3. Implementation of digital quality management systems.
4. Expansion of the biosimilars market.
5. Improved regulatory collaboration among countries.
The increasing number of these trends are expected to improve efficiency while providing for continued high quality.
Global pharmaceutical generating manufacturing is an important part of the pharmaceutical industry. Generics enable many millions of people around the world to access healthcare by providing lower-cost alternatives to branded products.
The generic drug industry presents pharmaceutical companies with great opportunity; however, it also creates challenges like competition, compliance with regulation and having to meet complicated manufacturing rules.
Pharmaceutical companies that focus on manufacturing of high-quality generics efficiently and comply with regulatory requirements will continue to have best position in the competitive generics market. Generics will continue to play a crucial role in helping to improve access to healthcare globally due to continuing demand for low-cost medications.
No comments:
Post a Comment
Please don't spam. Comments having links would not be published.